Biotech News
Filter News
Found 511,792 articles
-
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
-
After conducting a routine research-and-development review, Pfizer is easing away from preclinical biosimilar development. The bottom line is the company is ending five preclinical programs in its biosimilar area and cutting 150 positions.
-
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.
-
Merck’s Keytruda just keeps on proving its value to the company and patients. The company released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
-
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
-
The FDA approved Cabometyx based on the Phase III CELESTIAL trial that showed the drug provided a statistically significant and clinically meaningful improvement in median overall survival.
-
The partial government shutdown has entered day 24 and the pharma and medtech industry is beginning to feel the impact even more, particularly as the U.S. Food and Drug Administration grows more incapable of reviewing some medications for approval.
-
In a reflection on the annual healthcare conference, VC Bruce Booth criticizes the high cost of attending JPM, as well as the focus on market share instead of patients.
-
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
-
Wave Life Sciences is working to get its nucleic acid treatment, suvodirsen, for Duchenne muscular dystrophy (DMD) approved. DMD is a rare muscle-wasting disease that affects mostly boys, about 15,000 in the U.S.
-
Your Feedback Matters! Topics in 2019
1/15/2019
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about. -
MDA Awards Venture Philanthropy Grant to AcuraStem to Develop Novel Treatment for ALS
1/15/2019
The Muscular Dystrophy Association has awarded an MDA Venture Philanthropy (MVP) grant totaling $300,000 over two years to AcuraStem Incorporated to support preclinical development of a novel small molecule therapeutic for amyotrophic lateral sclerosis (ALS).
-
Prepared to address the nation's nursing shortage, Rush's College of Nursing ranked 4th in U.S. News & World Report's Online Programs
1/15/2019
Rush University College of Nursing ranks 4th among 179 schools listed in the graduate nursing programs category in U.S. News & World Report's 2019 Best Online Programs list released today.
-
CannAmerica Issues Options
1/15/2019
CANNAMERICA BRANDS CORP. ("CannAmerica" or the "Company") (CSE: CANA) (OTCQB: CNNXF) has granted an aggregate of 2,450,000 incentive stock options to purchase common shares to certain officers, directors, and other eligible persons of the Company.
-
Maxor and Relay Network Improve Patient Care with Digital Engagement Program That Drives 35 Percent Faster Refills Among At-Risk Patients and Wins Award
1/15/2019
Maxor National Pharmacy Services, LLC (Maxor), parent company to PBM MaxorPlus, and Relay Network, a mobile-engagement platform, were honored as a "Digital Campaign of the Year" in Modern Healthcare's 2018 Healthcare Marketing Impact Awards for their myMaxorLink™ campaign.
-
Boston Grants Ascend Massachusetts Approval to Open the First Adult-Use Cannabis Retail Store
1/15/2019
Ascend Massachusetts, a wholly owned subsidiary of Ascend Wellness Holdings (AWH), announced today that it was awarded the first conditional-use permit for adult-use cannabis retail sales in the city of Boston.
-
Green Peak Innovations Introduces Skymint Brand For State's Largest Vertical Cannabis Company
1/15/2019
Lansing-based Green Peak Innovations (GPI) is introducing the Skymint brand for Michigan's largest medical marijuana operation that includes growing, processing and provisioning centers.
-
Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities
1/15/2019
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on its development pipeline, comprising five clinical-stage cancer programs in various solid tumor types and addressing multiple cell types in the tumor microenvironment.
-
Nuo Therapeutics Announces Corporate Update Conference Call
1/15/2019
Nuo Therapeutics, Inc. (OTCQB: AURX) ("Nuo" or the "Company"), today announced plans to conduct a conference call to provide a corporate update and respond to questions, particularly with respect to steps it is taking as a result of its discussions with representatives of the Coverage and Analysis Group (CAG) of the Centers for Medicare & Medicaid Services.
-
The National Foundation to End Child Abuse and Neglect Announces New Board Members
1/15/2019
The National Foundation to End Child Abuse and Neglect (EndCAN) announced today the addition of five board members whose diverse set of skills and experiences will further EndCAN's mission to end child abuse and neglect in our lifetimes. Their terms begin immediately.